The investigators propose to use positron emission tomography (PET) imaging to determine
whether nicotinic receptor availability at pretreatment predicts smoking cessation success.
The investigators will recruit 30 smokers from those enrolled in the Pharmacogenetics of
Nicotine Addiction Treatment clinical trial. The investigators will measure nicotinic
receptor availability using the PET radioligand 2-[18F]FA, after overnight abstinence and
prior to initiation of treatment.